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Summary
Fixed-dose combinations of inhaled corticosteroids (ICSs) and long-acting b2-agonists (LABAs)
have been used to manage asthma for several years. They are the preferred therapy
option for patients who do not achieve optimal control of their asthma with low-
dose ICS monotherapy. In Europe, four ICS/LABA products are commercially available
for asthma maintenance therapy (ﬂuticasone propionate/formoterol fumarate, ﬂuticasone
propionate/salmeterol xinafoate, budesonide/formoterol fumarate and beclometasone
dipropionate/formoterol fumarate), and other combinations are likely to be developed
over the next few years (e.g. mometasone/formoterol fumarate, ﬂuticasone furoate/
vilanterol, mometasone/indacaterol). Data from randomized, controlled, clinical trials do
not demonstrate a clear overall efﬁcacy difference among ICS/LABA combinations approved
for asthma therapy. Conversely, pharmacological data indicate that there may be certain
advantages to using one ICS or LABA over another because of the speciﬁc pharmacodynamic
and pharmacokinetic proﬁles associated with particular treatments. This review article
summarizes the pharmacological characteristics of the various ICSs and LABAs available for
the treatment of asthma, including the potential for ICS and LABA synergy, and gives an
insight into the rationale for the development of the latest ICS/LABA combination approved
for asthma maintenance therapy.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Inhaled corticosteroids (ICSs) are the cornerstone of
asthma therapy.1 For patients with persistent or uncon-
trolled asthma for whom low-to-medium doses of ICSs
are insufﬁciently effective, there may be reluctance to
increase the steroid dose because of concerns about
corticosteroid-related adverse events.2 Instead, patients
may be prescribed a combination of an ICS and a long-acting
b2-agonist (LABA). A substantial body of evidence from
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randomized controlled trials indicates that addition of a
LABA to existing ICS therapy is clinically more effective than
increasing the dose of ICS monotherapy,3 5 even when taking
into consideration the heterogeneity observed in patient
responses to asthma controller medications.6 The use of
LABAs without concomitant use of an ICS is contraindicated
in patients with asthma because LABA monotherapy is
less effective than treatment with an ICS1,7 and there
are concerns regarding its safety.1 Robust data (compiled
from 42 randomized, double-blind studies that included
over 23,000 patients) demonstrate that there is no increased
risk of asthma-related hospitalization or asthma-related
deaths and that there is a low incidence of all-cause death
and asthma-related intubation associated with treatment
0954-6111/$ see front matter © 2012 Elsevier Ltd. All rights reserved.
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containing the LABA formoterol (with concomitant ICS
therapy) compared with non-LABA-containing therapy.8
However, the investigators acknowledge that because
events such as asthma-related deaths are rare, even the
large dataset included in this analysis was not sufﬁcient
in size to rule out completely a potential risk of serious
asthma-related events.8 An alternative to adding a LABA
to ICS therapy for asthma that is not controlled on low-
to-medium dose ICS monotherapy is to add a leukotriene
receptor antagonist (LTRA). This approach may be effective
in some patients, again relative to the heterogeneity of
patient responses to asthma treatments,1,6 and LTRAs have
also been shown to produce an additive effect when
combined with ICS therapy.9,10 The results of a recently
completed pragmatic, open-label study have suggested that
a LTRA has broadly equivalent efﬁcacy to a LABA as an add-
on to ICS therapy across a broad range of patients with
asthma in primary care.11,12 However, the results of several
randomized controlled trials have demonstrated that an
ICS/LABA combination is a superior treatment option to
combined LTRA/ICS.13 16 Thus, concomitant ICS and LABA
therapy remains the mainstay for step-up therapy from
ICS monotherapy.1 Other therapeutic approaches, such as
adding sustained-release theophylline, may be considered,
should treatment with a combination of an ICS and a LABA
fail to achieve adequate asthma control.1 If asthma remains
uncontrolled, the addition of anti-immunoglobulin E (IgE)
antibodies, in selected patients, might be prescribed.1
Other classes of drug may also provide an improvement
in asthma when added to ICS treatment as an alternative to
increasing the dose of ICS monotherapy. Recently it has been
shown that tiotropium, a long-acting anticholinergic agent,
is as effective as salmeterol for improvement in forced
expiratory volume in 1 second (FEV1) and peak expiratory
ﬂow (PEF) when added to ICS therapy, and gives results that
are superior to those achieved by doubling the ICS dose.17
Another study showed that tiotropium improves lung
function (FEV1) and time to ﬁrst exacerbation in patients
whose asthma is not adequately controlled with ICS/LABA.18
However, tiotropium is currently only approved for the
treatment of chronic obstructive pulmonary disease.19
Compared with concurrent ICS and LABA therapy ad-
ministered via separate inhalers, single inhalers that
contain an ICS/LABA combination have been shown to
provide improved efﬁcacy in a clinical trial20 and in a
meta-analysis of four studies.21 Moreover, compared with
concurrent ICS and LABA therapy, combination ICS/LABAs
can increase real-world patient adherence to their treat-
ment regimen.22 25 This may help to facilitate therapy
effectiveness in practice. To date, reasons for improved
clinical efﬁcacy with a ﬁxed-dose combination have not
been fully established, but it has been proposed that co-
deposition of ICS and LABA molecules in the lung may
enhance their therapeutic effects,21 as described later in
this review. In Europe, four ICS/LABA combinations are
now commercially available for the treatment of asthma
(ﬂuticasone propionate/formoterol fumarate, ﬂuticasone
propionate/salmeterol xinafoate, budesonide/formoterol
fumarate and beclometasone dipropionate/formoterol fu-
marate) and more are likely to become available within
the next few years (e.g. mometasone/formoterol fumarate,
ﬂuticasone furoate/vilanterol, mometasone/indacaterol).
Data from randomized clinical trials indicate that although
the available ICS/LABA combinations seem to offer some
differential advantages in terms of their effects on
speciﬁc markers of lung function and asthma control,
overall there appears to be little difference in their
efﬁcacy and safety proﬁles.26 29 However, the various
available ICSs and LABAs are associated with speciﬁc
pharmacological characteristics.30 32 An understanding of
the pharmacological proﬁles of ICSs and LABAs could help
to inform appropriate treatment selection by physicians.
This review provides a summary of the pharmacological
proﬁles of ICSs and LABAs, which may inﬂuence therapy
effectiveness, with a particular focus on the most recent
ICS/LABA combination to be developed for the treatment
of asthma: ﬂuticasone propionate (ﬂuticasone)/formoterol
fumarate (formoterol; ﬂutiform®).
ICSs and LABAs: unravelling the synergy story
ICSs potentiate LABA effects in vitro and in vivo
It has long been established that corticosteroids affect
b2-receptor-mediated signal transduction;33 the b2-receptor
gene is responsive to transcriptional up-regulation in
response to glucocorticoid exposure.34 37 Long-term admin-
istration of a LABA leads to down-regulation of b2-receptors,
a process associated with b-agonist tolerance.38,39 However,
corticosteroids provide a protective mechanism against
the down-regulation of b2-receptors following b-agonist
treatment.39 For example, the results of in vivo studies
show that, in rat lung tissue, the b-agonist isoproterenol
decreases b2-receptor numbers by around 50%, a process
prevented by co-administration of the corticosteroid dexa-
methasone.39 Indeed, the results of historical studies have
shown that co-administration of an ICS and a LABA may even
increase b2-receptor density and function, both in vitro and
in vivo . In bovine airway smooth muscle, dexamethasone
was found to increase the number of isoproterenol binding
sites with no adverse effect on receptor-binding afﬁnity,40
while beclometasone dipropionate applied to human nasal
mucosa in vivo has been found to increase b2-receptor
gene mRNA levels.37 More recently, results of in vitro
studies demonstrated that in addition to these b2-receptor-
mediated events, ﬂuticasone and budesonide increase
airway retention of LABAs. Increased retention is observed
with more cationic (e.g. formoterol), but not with more
lipophilic (e.g. salmeterol) LABAs, and occurs through rapid
inhibition of organic cation transporters, and attenuation
of uptake and disposal of the LABA by smooth muscle and
vascular cells, respectively.41
The steroid-sparing effect of LABAs: anti-
inﬂammatory actions in vitro
The primary effect of LABAs is on b2-receptors, but, in
addition to their bronchodilatory action, LABAs comple-
ment the effects of corticosteroids via interaction with
glucocorticoid signal transduction.42 LABAs can activate
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glucocorticoid receptors43 and enhance the transcription
of anti-inﬂammatory mediators.44,45 For example, in vitro
gene transcription induced by dexamethasone, budesonide
or ﬂuticasone via the glucocorticoid response element is
increased by addition of a LABA.44 Moreover, maximal
corticosteroid-induced responses have been observed at
10-fold lower concentrations of an ICS in the presence of
a LABA.44 In a series of in vitro studies using human airway
smooth muscle cells, formoterol and budesonide were found
to activate glucocorticoid receptors; the combination of the
two agents at lower doses enhanced receptor activity more
than when administered separately.43 Thus, LABAs have
a steroid-sparing effect in vitro .46 Interactions between
LABAs and corticosteroid-related gene transcription have
also been demonstrated in patients with asthma, with
co-administration of salmeterol and ﬂuticasone leading
to enhanced glucocorticoid receptor nuclear translocation
compared with ﬂuticasone monotherapy.42 Glucocorticoid-
independent anti-inﬂammatory effects of LABAs have also
been demonstrated in vitro; budesonide combined with
formoterol or salmeterol inhibited cytokine release in
bronchial epithelial cells by 85% (as compared with a 50% in-
hibition of cytokine release observed when any of the drugs
was administered alone). Unlike glucocorticoid-mediated
inhibition, formoterol-dependent inhibition of cytokine
release was not altered by reduced glucocorticoid-receptor
expression.45 In practice, LABA monotherapy has not been
shown to provide clinically important anti-inﬂammatory
effects;47 indeed, treatment with a LABA alone appears to
be ineffective in maintaining asthma control, and clearly
less effective than with an ICS alone.48 However, this point is
of limited relevance in routine practice because prescription
of a LABA without a concomitant ICS is not recommended in
asthma therapy.1
The steroid-sparing effect of LABAs:
antiproliferative actions in vitro
Bronchial smooth muscle growth is accelerated in asthma,
even in patients with milder forms of the disease,49
which can result in bronchial hyper-reactivity.43 In addition
to their anti-inﬂammatory effects, ICSs and LABAs have
antiproliferative properties. Glucocorticoids and b2-agonists
both inhibit proliferation of airway smooth muscle cells
in vitro.43 Not only can LABAs activate the glucocorticoid
receptor directly, but they also act via transcription
factors, such as CCAAT/enhancer binding protein-a (CEBPa),
which regulates smooth muscle cell proliferation.43 In
combination, LABAs and ICSs, can simultaneously activate
glucocorticoid receptors and CEBPa, which stimulates the
promoter p21Waf1/Cip1 (a cell cycle inhibitor protein).
Consequently, the proliferation of smooth muscle mass is
suppressed.43
The proposed synergistic or additive mechanisms of
ICSs and LABAs in the inhibition of cell proliferation in
smooth muscle are shown in Fig. 1.43 However, the exact
signal transduction processes involved are not yet fully
understood. A key characteristic of airway smooth muscle
cells in asthma is the low level of CEBPa expression.
It is thought that many of the pathological and clinical
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Figure 1. Proposed mechanisms of inhaled corticosteroid and
long-acting b2-agonist modulation of airway smooth muscle
cell proliferation.43 cAMP, cyclic adenosine monophosphate;
CCAAT, cytosine - cytosine - adenosine - adenosine - thymidine;
CEBPa, CCAAT/enhancer binding protein-a; GC, glucocorticoid;
p21Waf1/Cip1, cell cycle inhibitor; PKA, protein kinase. Reprint-
ed from Roth M, et al., Interaction between glucocorticoids
and beta2 agonists on bronchial airway smooth muscle cells
through synchronised cellular signalling. The Lancet 2002;
360(9342):1293 9. Copyright 2002, with permission of Elsevier.
features of asthma, including inﬂammation, remodelling
and airway hyper-responsiveness, could be explained by this
deﬁcit.50 Moreover, in vitro , the antiproliferative effects
of corticosteroids are reduced in asthmatic airway smooth
muscle cells compared with those from healthy controls;51
this may be due to the deﬁcit in CEBPa. Findings from more
recent in vitro studies also indicated that there may be
differences in CEBPa signalling in asthmatic and healthy
airway smooth muscle cells.52,53 For example, the LABA
formoterol is reported to induce dose-dependent reductions
in serum-induced proliferation of smooth muscle cell in both
asthmatic and healthy cells; however, signal transduction
in the asthmatic cells occurred via the cyclin-dependent
kinase inhibitor p27Kip, a cell cycle regulator, whereas
LABA-mediated signalling in healthy cells occurred via
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p21Waf1. Interestingly, with the addition of a corticosteroid
(ﬂuticasone, dexamethasone or budesonide), the maximal
antiproliferative effects of formoterol observed in vitro
were approximately doubled in the asthmatic cells.52
The exact mechanisms by which ICSs and LABAs interact
in vivo, either synergistically or additively, remain to
be elucidated.54 However, these in vitro data indicate
that both LABAs and ICSs suppress smooth muscle cell
proliferation. This effect is enhanced when both drug classes
are present, further supporting the potential clinical
importance of using these drugs in combination in asthma
therapy.
The effect of ICSs and LABAs on airway remodelling
in asthma
Airway obstruction in asthma involves the remodelling
of bronchial smooth muscle. Airway remodelling includes
epithelial changes, thickening of the basement membrane
(subepithelial ﬁbrosis), inﬂammatory cell inﬁltration, hy-
perplasia and hypertrophy of the bronchial smooth muscle,
and mucus hypersecretion.55 The signalling mechanisms
that underpin these remodelling processes are complex.
Formation of subepithelial ﬁbrosis is a key feature of
airway remodelling and involves the deposition of types
I and III collagen.55 Therefore, signalling mediators re-
sponsible for subepithelial ﬁbrosis (proﬁbrotic cytokines:
interleukin [IL]-11, IL-17 and transforming growth factor
b [TGF-b]) and collagen levels are elevated in asthmatic
airways.
Although corticosteroids reduce airway inﬂammation and
levels of several proﬁbrotic cytokines, they may not fully
suppress collagen deposition. Indeed, a study examining
the effect of oral corticosteroids on ﬁbrotic cytokines in
bronchial biopsy specimens of patients with moderate-to-
severe asthma determined that, while the expression of
IL-11 and IL-17 was lowered to levels similar to those
seen in patients with mild asthma and normal controls,
corticosteroids did not reduce elevated TGF-b levels. This
ﬁnding may explain the observed lack of effect of oral
corticosteroids on collagen types I and III deposition.55
Recent in vitro ﬁndings have highlighted the importance
of LABA actions on collagen deposition, further emphasising
the potential additive effects of LABAs and ICSs in the
treatment of asthma.53 In TGF-b-stimulated airway smooth
muscle cells, formoterol reduced levels of collagen (types
I, III and IV) in a dose-dependent manner.53 In the
presence of a corticosteroid (ﬂuticasone, dexamethasone
or budesonide), formoterol further reduced collagen levels
(types I and III, but not IV). Therefore, LABAs (in this
case formoterol) appear to have the potential to reduce
airway remodelling and in combination with a corticosteroid
this inhibitory effect is enhanced in vitro ;53 however,
the clinical beneﬁts of any possible additive effects are
currently unknown.
The importance of drug co-deposition
The enhanced effects of ICSs and LABAs can occur if the
two compounds are administered concurrently (via a single
or separate inhalers), but there is evidence to suggest that
molecular interaction can be enhanced by co-administration
of ICS and LABA via a single delivery device. Theophilus
and colleagues used Raman laser spectroscopy together with
an Andersen Cascade Impactor to demonstrate that co-
deposition of salmeterol and ﬂuticasone was signiﬁcantly
greater when they were administered via one inhaler
rather than via two separate inhalers.56 Importantly,
ICS/LABA interactions may translate into improved clinical
effectiveness compared with ICSs and LABAs administered
concurrently via separate inhalers. A meta-analysis of four
randomized, double-blind trials showed that ﬂuticasone/
salmeterol ﬁxed-dose combination therapy is associated
with a signiﬁcantly greater improvement in lung function
(as measured by morning PEF) compared with the same
drugs administered concurrently via separate inhalers.21
Data from a later study by Huchon and colleagues provided
further support for the clinical importance of co-deposition
and enhanced synergy of ICSs and LABAs in patients with
asthma; although the beclometasone/formoterol ﬁxed-dose
combination and its separate components administered
concurrently provided similar improvements in morning PEF,
the ﬁxed-dose combination was signiﬁcantly superior to its
separate components administered concurrently in terms
of improving markers of asthma control.20 It has been
postulated that physical practicalities of a patient inhaling
both drugs via a single device in a single breath, compared
with using separate inhalers, may maximize the potential for
drug co-deposition, perhaps facilitating greater interaction
between the ICS and the LABA.21
Pharmacological proﬁles of ICSs
ICSs work by both suppressing the actions of pro-
inﬂammatory transcription factors, such as nuclear factor
kappa b and activator protein 1, and enhancing the
activity of anti-inﬂammatory cytokines, including inhibitory
molecule for nuclear factor kappa b1, IL-10 and IL-12.57,58
Pharmacological characteristics that could theoretically
optimize ICS effectiveness include a low oral and a high
pulmonary bioavailability, high receptor-binding afﬁnity,
high protein-binding capacity and a long pulmonary reten-
tion time (Table 1).30,59,60 ICSs differ in terms of their
speciﬁc pharmacological proﬁles, and variation in potency
among the available ICSs is related to speciﬁc differences in
pharmacokinetic and pharmacodynamic properties. Flutica-
sone propionate is one of the most potent ICSs30 and the
reasons for its high potency are described below.
The oral bioavailability of ﬂuticasone is very low (1%),
similar to that of ciclesonide (for both the inactive pro-drug
and its active metabolite, desisobutyryl-ciclesonide [des-
ciclesonide])61 and mometasone furoate (mometasone; Ta-
ble 2).59,60 This compares with a much higher bioavailability
observed with budesonide (11%) and beclometasone dipropi-
onate (~15%; ~26% for the active metabolite beclometasone-
17-monopropionate).30,60 A low oral bioavailability could
translate into a lower potential for systemic availability and
systemic side effects via decreased absorption of swallowed
drug from the gastrointestinal tract,30,60 although the
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clinical beneﬁts of low oral bioavailability remain to be
established. A high pulmonary bioavailability is important
for drug efﬁcacy, but as this is a measure of drug that is
absorbed through the lungs, a high pulmonary bioavailability
also increases the potential for systemic absorption and
adverse effects.30,60 Relative pulmonary bioavailabilities
for ICSs have been reported as 11% for mometasone,
20% for ﬂuticasone, 15 30% for budesonide, 50 60% for
beclometasone and 50% for ciclesonide (Table 2).59 How-
ever, reported pulmonary bioavailabilities vary and can be
affected by the device and drug formulations tested, as
well as by the sensitivity of the assay used to obtain these
values.62,63 Given that pulmonary bioavailability impacts
on both the efﬁcacy and safety potential of an ICS, this
pharmacological property must be evaluated in line with
other characteristics such as protein-binding capacity and
receptor afﬁnity.30
A high protein-binding capacity is associated with a
reduced risk of systemic effects; with an increase in
protein binding, the systemic availability of the drug
is decreased.63 Of the ICSs currently used in asthma
therapy, ﬂuticasone, ciclesonide and mometasone have
the highest protein-binding capacities.60 Pharmacological
data indicate that a high receptor-binding afﬁnity is an
important attribute of an ICS because it translates into
a high anti-inﬂammatory capacity.64 However, this should
be considered in light of other parameters (such as oral
and pulmonary bioavailabilities) as a high receptor-binding
afﬁnity may also be associated with an increased risk of
systemic adverse events.30 The relative receptor-binding
afﬁnity (versus dexamethasone) of ﬂuticasone is second only
to mometasone (Table 2);59 however, the inhalation half-life
of mometasone is much lower than that of ﬂuticasone.60
Inhalation half-life is another critical property for an ICS
because it relates to pulmonary retention time (the rate at
which ICSs are absorbed across the pulmonary membranes
and out of the airways),30 which is discussed further below.
Lipophilicity affects the speed at which an ICS can
enter cells across the phospholipid bilayer, bind to
glucocorticoid receptors and take effect. The lipophilic
properties of ICSs also correlate with pulmonary retention
time (inﬂuencing the duration of therapeutic effect) and
volume distribution of the drug (a measure of the drug
concentration in the plasma relative to the total amount of
drug in the body).30,60 Fluticasone is the most lipophilically
active ICS, and therefore has a long duration of anti-
inﬂammatory action.30 Although the pro-drug ciclenoside
is reported to be more lipophilic than ﬂuticasone, its
active metabolite des-ciclesonide has a markedly lower
lipophilicity.60 Pulmonary retention times for ﬂuticasone,
des-ciclesonide and budesonide are long;63 their speciﬁc
lipophilic properties manifest in a slow dissolution rate in
the lungs (for ﬂuticasone) or lipid conjugation mechanisms
(for des-ciclesonide and budesonide).63 Fluticasone, des-
ciclesonide and beclometasone 17-monopropionate also
have the highest volume of distribution levels (which
equates to a greater amount of drug in the tissue and a lesser
amount in the plasma).30,59 The lipophilicity of an ICS is,
therefore, an important determinant of its pharmacological
effects and should be considered when selecting one of
S14 M. Tamm et al.
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these drugs for the treatment of asthma.30,60 Importantly,
ﬂuticasone has a clearance rate that is similar to the normal
rate of liver blood ﬂow (69 versus 81 L/h, respectively).60,65
Its rate of systemic clearance is slower than that of
some other ICSs,60 but it also undergoes a high level of
ﬁrst-pass metabolism. These properties help to maintain
its low systemic availability,30,66 and, together with its
high relative potency,30 these characteristics contribute
to its favourable pharmacokinetic and pharmacodynamic
risk beneﬁt proﬁle.
Pharmacological proﬁles of LABAs
Important properties for a LABA include speed of onset
of action, duration of action and agonist activity at
the b2-receptor. As shown in Table 3, the properties
of formoterol are favourable compared with those of
salmeterol, the only other LABA currently available as
a component of a ﬁxed-dose combination product in
Europe.31,32,67 73 Formoterol is the fastest acting inhaled
LABA available for the treatment of asthma;32,72,73 in
patients with the disease it has a bronchodilatory action
that is as rapid as that of salbutamol31,32,72 74 (~1 3
minutes)75 and considerably quicker than that of salmeterol
(Table 3).32,72 The median reported time to onset of
signiﬁcant bronchodilation (assessed as time to ﬁrst increase
in FEV1 15% compared with baseline within 1 hour of
inhalation) is between ~3 and ~12 minutes for formoterol
(for 24mg and 12mg, respectively) and ~30 minutes for
salmeterol (50mg) (Table 3).32 Moreover, the increase in lung
function observed with formoterol (24mg) at 1 minute post-
dose (44% increase in speciﬁc airway conductance [sGaw])
is nearly three times greater than that observed with
salmeterol (50mg) at 3 minutes post-dose (16% increase in
sGaw) in patients with moderate-to-severe asthma.31
The differences in speed of onset of action observed
between formoterol and salmeterol may be related to
differences in their lipophilicity.76 LABA lipophilicity may
also be associated with the duration of its action. Formoterol
is moderately lipophilic and is taken up within the
cell membrane to form a depot, from where it leaches
out to interact with b2-receptors. Salmeterol is more
lipophilic than formoterol so it quickly partitions into the
cell membrane where, instead of leaching back out of the
cell, it slowly approaches the active site of the b2-receptor
by diffusing back through the phospholipid bilayer.76
Salmeterol is also known to bind to auxiliary binding sites
on the b2-receptor known as exosites, and the head of the
molecule is able to repeatedly engage and disengage with
the active site by means of the hinge principle.76 This means
that, in vitro , salmeterol has a slightly longer duration of
action than formoterol;77 however, this characteristic is not
observed in vivo (Table 3).32
The duration of bronchodilatory action of formoterol
is ~12 hours in patients with asthma across all licensed
doses,75 although a duration of action of up to 24 hours
has been reported;78 80 this is substantially longer than
that of salbutamol and similar to that of salmeterol
(Table 3).32,76,78 Compared with salmeterol, formoterol
has a higher intrinsic efﬁcacy and is therefore a full,
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rather than partial, agonist at the b2-receptor.71 Thus,
a study in patients with asthma found that formoterol
showed greater efﬁcacy (as measured by protection against
methacholine-induced bronchoconstriction) with increasing
doses, while the dose response curve for salmeterol was
much ﬂatter.71 The b2-receptors exist in two conformations,
activated and inactivated, and they oscillate between the
two forms. Full agonists are thought to shift the balance
completely in the direction of the activated form, whereas
partial agonists stabilize either conformation.76 Although
no randomized, controlled, clinical study data currently
demonstrate superiority of any LABA compared with other
options, the pharmacological attributes associated with
formoterol may be of relevance in the treatment of patients
with asthma in routine practice.32
Newer LABAs, which include indacaterol, carmoterol,
milveterol, vilanterol, BI-1744-CL, LAS-100977 and PF-
00610355,81,82 are in development for once-daily dosing in
asthma or chronic obstructive pulmonary disease. To date,
these molecules have been less extensively studied in
clinical trials than the well-established LABAs formoterol
and salmeterol,82 but their properties are likely to include
those that enable a long pulmonary retention time to
be achieved. Indacaterol has recently been launched in
Europe and is the ﬁrst once-daily LABA to be licensed for
the treatment of chronic obstructive pulmonary disease.82
Indacaterol undergoes membrane partitioning in a similar
way to salmeterol, but it has a high afﬁnity for the lipid raft
domain of the membrane, a characteristic that has been
associated with its longer duration of action compared with
salmeterol, as assessed by reversal of carbachol-induced
contraction of human small airways in vitro .83 Indacaterol
permeates back through the cell membrane at a faster
rate than salmeterol;84 however this does not appear be
associated with a faster onset of action compared with
formoterol.75,83,85
Tolerability of ICSs and LABAs
The overall safety and tolerability proﬁles of the ICSs
ﬂuticasone and budesonide (both as individual components
and when given together with a LABA) have been shown to
be broadly similar at clinically equivalent doses in meta-
analyses of several randomized controlled trials.26,86 The
LABAs formoterol and salmeterol have also been shown
to have similar safety and tolerability proﬁles.86,87 The
tolerability of beclometasone/formoterol appears to be
broadly comparable to that of budesonide/formoterol.28
Effects of inhaled particle size on drug
efﬁcacy
In addition to the in vitro and in vivo pharmacological char-
acteristics of ICSs and LABAs, the size of the drug particles
emitted by an inhaler also has the potential to inﬂuence
treatment effectiveness. Clearly, good pulmonary deposi-
tion is required for efﬁcacy, but this should be balanced
with the potential for local or systemic adverse effects.
The size of drug particles emitted by an inhaler affects
pulmonary deposition, potential pulmonary bioavailability
and lung volume distribution.30,61 The importance of inhaled
particle size is described in the article by Dissanayake and
colleagues in this supplement.88 In brief, a high level of
lung deposition, and thus the potential for a therapeutic
effect, correlates with the ﬁne particle fraction (the
proportion of an emitted dose that contains particles with
an aerodynamic diameter of <5mm).89 94 By contrast, large
S16 M. Tamm et al.
particles (>5mm) can be deposited in the mouth and throat,
which may be associated with local adverse effects.30,60
With the inhalers and drug formulations that are currently
available, particle size can vary widely, with various devices
having different ﬁne particle fraction characteristics. For
example, the ﬁne particle fraction emitted from dry-powder
inhalers can be relatively low (Turbuhaler : 6 18%; Diskus :
16 21%)95 and, for inhalers such as the Turbuhaler , this
proportion of the dose is largely determined by the patient’s
inhalation ﬂow rate.96,97 With hydroﬂuoroalkane (HFA)-
based aerosols the ﬁne particle fraction is often higher
(~40%),98 and the size of the drug particles emitted by these
aerosol devices is not always dependent on the patient’s
inhalation pattern.96 Lung deposition is also inﬂuenced
by delivery device, drug formulation and the inhalation
pattern of the user.96 In summary, ﬁne particle fraction
characteristics of ICS/LABA therapies and their associated
potential for deposition in the airways also contribute to the
treatment risk beneﬁt proﬁles.30
Conclusions
As highlighted throughout this review, the potential
effectiveness of any ICS/LABA combination is related
to the pharmacological characteristics of the individual
ICS and LABA components and the characteristics of
the delivery device. If the risk beneﬁt proﬁle of the
inhaled drug is favourable, it may be expected to be an
effective therapy, although this can only be conﬁrmed by
clinical trials in patients with asthma.99 Of the available
agents, the pharmacological properties of ﬂuticasone and
formoterol appear to offer a strong risk beneﬁt proﬁle
when assessed alongside those of other ICSs and LABAs
available for the treatment of asthma. However, it remains
unproven as to whether these pharmacological differences
translate into clinical beneﬁts. Fluticasone is a potent
and sustained-acting ICS;30,100 formoterol is a rapid-acting
bronchodilator that provides a faster bronchodilatory action
than salmeterol.71 73 Importantly, both ﬂuticasone and
formoterol have pharmacological attributes that support
the notion that this combination may provide an effective
therapy option in practice. It should be noted, however,
that at present no clinical trial in patients with asthma has
demonstrated signiﬁcant clinical differences between the
currently available combination products.
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